YHLO at Autoimmunity 2026: Joining Forces for Better Autoimmune Care
From May 14 to 17, 2026, the highly anticipated International Congress on Autoimmunity was grandly held in Prague, the capital of the Czech Republic.
The Autoimmunity Congress is the largest multidisciplinary meeting that discusses all aspects of the related diseases under one roof, offering courses and lectures by the world’s leading experts.
As an innovative representative in the in vitro diagnostics (IVD) field, YHLO showcased its comprehensive autoimmune disease diagnostic solutions. During the congress, YHLO successfully hosted a symposium titled "Precision in Autoimmunity: New Horizons in Diabetes Screening and APS Criteria," which received widespread attention and high acclaim.
Throughout the exhibition, YHLO showcased its comprehensive autoantibody testing solutions and key achievements, covering a broad test menu that includes antiphospholipid antibody syndrome (APS), autoimmune diabetes, and more. Built on four major technology platforms – chemiluminescence, immunoblotting, indirect immunofluorescence, and liquid chip – YHLO’s full-cycle solutions are designed to meet the diverse needs of laboratories at different levels.
With high-sensitivity and high-specificity assays combined with intelligent solutions, YHLO captured the attention and recognition of many experts at the congress, further strengthening its presence in the global autoimmune diagnostics market.
On the evening of May 15, YHLO successfully held its autoimmune symposium. Nearly 40 experts, physicians, and scholars in the autoimmune field from both China and abroad gathered together for in-depth discussions. Several invited experts delivered insightful keynote speeches.
YHLO’s academic representative systematically presented the company’s technological evolution and innovation in autoimmune disease diagnostics, highlighting its academic achievements both in China and internationally, as well as installations in top-tier medical institutions.
Other participating experts focused on cutting-edge topics such as autoimmune diabetes screening and antiphospholipid antibody syndrome (APS), sharing the latest research findings and clinical practices.
The symposium fostered a strong academic atmosphere, with experts presenting the latest dynamics in autoimmune disease diagnostics from multiple perspectives, from basic research to clinical translation. The successful symposium not only built a high-level academic exchange platform but also fully demonstrated YHLO’s professional strength and brand influence in the autoimmune diagnostics field.
With this successful participation in Autoimmunity 2026 in Prague and the symposium, YHLO has further consolidated its in-depth presence in autoimmune disease diagnostics and continues to expand the depth and breadth of international cooperation.
In the future, YHLO will increase R&D investment in autoimmune diseases and related interdisciplinary fields. It will also accelerate the deep integration of AI with autoimmune diagnostics, while continuously enriching its test menu and enhancing product performance.
Working hand in hand with global partners, YHLO is committed to benefiting patients worldwide with smarter, more precise diagnostic solutions.
Attachments:
Previous
Previous Page
MORE NEWS
YHLO at Autoimmunity 2026: Joining Forces for Better Autoimmune Care
YHLO showcased its autoimmune diagnostics at Autoimmunity 2026 in Prague.
2026-05-20
YHLO Joins BSI’s 125th Anniversary Gala in London
On April 23, YHLO Founder Mr. Hu Deming and Chairman Mr. Hu Kunhui attended BSI's 125th anniversary gala in London as the only Chinese IVD representatives.
2026-04-28
Meet YHLO PIFI: Smarter Islet Function Assessment
Launched on April 10 at the 2026 Islet Metabolism Forum in Nanjing, the YHLO PIFI Intelligent Computing Model marks a major step forward in diabetes care.
2026-04-14
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
